


Please cancel Claim 1-4.

5. (currently amended) A compound of formula I according to claim 1 wherein



R<sub>1</sub> represents hydrogen, lower alkyl, lower alkoxy-lower alkyl, or benzyl;

R<sub>2</sub> represents ~~lower alkyl, optionally substituted by one radical R<sub>3</sub>, by two phenyl groups, by two lower alkoxy-carbonyl groups, by phenyl and lower alkoxy-carbonyl, or by hydroxyphenyl and lower alkoxy-carbonyl; cyclopentyl; benzocyclopentyl; cyclohexyl; pyrrolidinyl; piperidinyl; N-lower alkylpiperidinyl; N-benzylpiperidinyl; N-pyrimidinylpiperidinyl; morpholinyl; azepinyl; oxazepinyl; phenyl; naphthalinyl; tetrahydronaphthalinyl; pyridyl; lower alkyl-pyridyl; quinolinyl; thienyl; lower alkoxy-carbonylmethylthienyl; or phenyl substituted by one or two substituents selected from the group consisting of lower alkyl, trifluoro-lower alkyl, hydroxy-lower alkyl, amino-lower alkyl, lower alkylamino-lower alkyl, di-lower alkylamino-lower alkyl, N-cyclohexyl-N-lower alkylamino-lower alkyl, lower alkoxy-carbonylpiperidino-lower alkyl, N-lower alkylpiperazino-lower alkyl, lower alkoxy-carbonyl-lower alkyl, hydroxy, lower alkoxy, trifluoro-lower alkoxy, 1H-imidazolyl-lower alkoxy, lower alkanoyloxy, benzoyloxy, carboxy, lower alkoxy-carbonyl, carbamoyl, lower alkylcarbamoyl, amino, lower alkanoylamino, benzoylamino, amino mono- or disubstituted by lower alkyl, by hydroxy-lower alkyl or by lower alkoxy-lower alkyl, 1H-imidazolyl, lower alkyl-1H-imidazolyl, carboxy-1H-imidazolyl, lower alkyl-estercarboxy-1H-imidazolyl, pyrrolidino, piperidino, piperazino, N-lower alkylpiperazino, morpholino, sulfamoyl, lower alkylsulfonyl, phenyl, pyridyl, halogenyl, or benzoyl; and~~  
R<sub>3</sub> represents ~~hydroxy, lower alkoxy, lower alkanoyloxy, benzoyloxy, carboxy, lower alkoxy-carbonyl, carbamoyl, amino, lower alkylamino, di-lower alkylamino, phenylamino, N-lower alkyl-N-phenylamino, pyrrolidino, oxepyrrolidino, piperidino, morpholino, imidazolino, oximidazolino, cyclopropyl, cyclopentyl, cyclohexyl, tetrahydrofuranyl, phenyl, naphthalinyl, tetrahydronaphthalinyl, furyl, a mono- or bicyclic heteroaryl group comprising one or two nitrogen atoms, which heteroaryl group is unsubstituted or mono- or disubstituted by lower alkyl, hydroxy and lower alkoxy, or phenyl substituted by one or two substituents selected from the group consisting of lower alkyl, trifluoro-lower alkyl, lower alkoxy-carbonyl-lower alkyl,~~

~~hydroxy, lower alkoxy, trifluoro lower alkoxy, lower alkanoyloxy, benzoyloxy, carboxy, lower alkoxy carbonyl, carbamoyl, amino, lower alkanoylamino, benzoylamino, amino mono- or disubstituted by lower alkyl, by hydroxy lower alkyl or by loweralkoxy lower alkyl, pyrrolidino, piperidino, morpholino, piperazino, N-lower alkylpiperazino, N-lower alkoxy carbonylpiperazino, phenyl, pyridyl, 1H-imidazolyl, lower alkyl-1H-imidazolyl, sulfamoyl, lower alkylsulfonyl, halogenyl, or benzoyl; or wherein~~

~~R<sub>1</sub> and R<sub>2</sub> together represent alkylene with four or five carbon atoms, optionally mono- or disubstituted by phenyl, hydroxy, amino, benzoylamino, or piperidino; benzalkylene with four or five carbon atoms in the alkylene group; oxaalkylene with one oxygen and four carbon atoms; or azaalkylene with one nitrogen and four carbon atoms wherein nitrogen is unsubstituted or substituted by lower alkyl, phenyl lower alkyl, lower alkoxy carbonyl lower alkyl, carbamoyl lower alkyl, pyrrolidinocarbonyl lower alkyl, morpholinocarbonyl lower alkyl, cyclopentyl, lower alkoxy carbonyl, phenyl, methoxyphenyl, trifluoromethylphenyl, pyridinyl; pyrimidinyl, or pyrazinyl;~~

~~R<sub>4</sub> represents hydrogen, lower alkyl or halo or methyl;~~

~~and or a N-oxide or a pharmaceutically acceptable salts thereof of such a compound.~~

6. (currently Amended) A compound of formula I according to claim 4 5 wherein

R<sub>1</sub> represents hydrogen;

R<sub>2</sub> represents phenyl substituted by trifluoromethyl and optionally a further substituent selected from the group consisting of hydroxy-lower alkyl, lower alkylamino, hydroxy-lower alkylamino, di-lower alkylamino, 1H-imidazolyl, lower alkyl-1H-imidazolyl, carbamoyl, lower alkylcarbamoyl, pyrrolidino, piperidino, piperazino, lower alkylpiperazino, morpholino, lower alkoxy, trifluoro-lower alkoxy, phenyl, pyridyl, and halogenyl;

R<sub>4</sub> represents methyl;

~~and or a N-oxide or a pharmaceutically acceptable salts thereof of such a compound.~~

7. (currently amended) A compound of formula I according to claim 4 5 wherein

R<sub>1</sub> represents hydrogen;

R<sub>2</sub> represents phenyl substituted by 3-trifluoromethyl and optionally a further substituent selected from the group consisting of 1-hydroxy-1-methylethyl, methylamino, ethylamino, 2-hydroxy-1-propylamino, 2-hydroxy-2-propylamino, diethylamino, 1H-imidazolyl, 2- and 4-methyl-1H-imidazolyl, carbamoyl, methylcarbamoyl, pyrrolidino, piperidino, piperazino, 4-methylpiperazino, morpholino, methoxy, trifluoromethoxy, 2,2,2-trifluoroethoxy, phenyl, 2-, 3- and 4-pyridyl, chloro, and fluoro;

R<sub>4</sub> represents methyl;


~~and or a N-oxide or a pharmaceutically acceptable salts thereof of such a compound.~~

8. (currently amended) The compound of formula I according to claim 4 5 wherein  
 R<sub>1</sub> represents hydrogen;  
 R<sub>2</sub> represents 3-(1-hydroxy-1-methylethyl)-5-(trifluoromethyl)phenyl;  
 R<sub>4</sub> represents methyl;  
 and or a N-oxide or a pharmaceutically acceptable salts thereof ~~of such a compound~~.


9. (currently amended) A compound according to ~~any one of~~ claim 4 5 wherein  
 R<sub>1</sub> is hydrogen;  
 R<sub>2</sub> represents phenyl which is mono- or disubstituted by imidazol-lower alkoxy, lower alkyl amino, trifluoromethyl, hydroxy lower alkyl amino, bis-(lower alkoxy lower alkyl) amino, lower alkyl piperaziny, piperidiny, pyrrolidiny, morpholiny, phenyl, pyridyl, imidazolyl which is unsubstituted or mono- or disubstituted by lower alkyl or N-lower alkyl carbamoyl;  
 R<sub>4</sub> is lower alkyl;  
 and or a N-oxide or a pharmaceutically acceptable salts thereof ~~of such a compound~~.

10. (cancelled)

11. (currently amended) A process for the synthesis of a compound of the formula



or an N-oxide or a salt thereof, wherein the symbols R<sub>1</sub>, R<sub>2</sub> and R<sub>4</sub> are as defined in claim 1,  
 characterized in that a compound of formula II



wherein R<sub>4</sub> is as defined for a compound of formula I, ~~or a derivative thereof~~ wherein the carboxy group -COOH is in activated form, is reacted with an amine of the formula III



(III)

wherein R<sub>1</sub> and R<sub>2</sub> are as defined for a compound of the formula I, optionally in the presence of a dehydrating agent and an inert base and/or a suitable catalyst, and optionally in the presence of an inert solvent;

where the above starting compounds II and III may also be present with functional groups in protected form if necessary and/or in the form of salts, provided a salt-forming group is present and the reaction in salt form is possible;

any protecting groups in a protected derivative of a compound of the formula I are removed;

and, if so desired, an obtainable compound of formula I is converted into another compound of formula I or a N-oxide thereof, a free compound of formula I is converted into a salt, an obtainable salt of a compound of formula I is converted into the free compound or another salt, and/or a mixture of isomeric compounds of formula I is separated into the individual isomers.

12. (currently amended) A pharmaceutical composition comprising as an active ingredient a compound of formula I according to ~~any one of claims 1 to 10~~ Claim 5 or a N-oxide or a pharmaceutically acceptable salt thereof together with a pharmaceutically acceptable carrier.

13. (currently amended) A method for the treatment of ~~a disease which responds to an inhibition of protein kinase activity, leukaemias~~ which comprises administering a compound of formula I according to ~~any one of claims 1 to 10~~ claim 5 or a N-oxide or a pharmaceutically acceptable salt thereof.

14. (cancelled)

15. (new) 4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl]benzamide or an N-oxide or pharmaceutically acceptable salts thereof.

16. (new) A compound of formula I according to claim 5 wherein

R<sub>1</sub> represents hydrogen;

R<sub>2</sub> represents phenyl substituted by 3-trifluoromethyl and a further substituent selected from the group consisting of 2-methyl-1H-imidazolyl and 4-methyl-1H-imidazolyl;

R<sub>4</sub> represents methyl;

or a N-oxide or pharmaceutically acceptable salts thereof.

17. (new) A compound of formula I according to claim 5 wherein

R<sub>1</sub> represents hydrogen;

R<sub>2</sub> represents phenyl substituted by 5-trifluoromethyl and optionally a further substituent selected from the group consisting of 2,4-dimethyl-1H-imidazolyl, 5-methyl-1H imidazolyl, 2-methoxymethylamino, propoxy, ethoxy, methylaminocarbonyl, benzoyl, 4-methoxy-2-methyl, acetylamino 2,4-dimethyl-1H-imidazolyl, acetic acid ethyl ester, piperidine carboxylic acid ethyl ester;

R<sub>4</sub> represents methyl;

or a N-oxide or pharmaceutically acceptable salts thereof.